GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Provexis PLC (LSE:PXS) » Definitions » Gross Margin %

Provexis (LSE:PXS) Gross Margin % : 35.57% (As of Sep. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Provexis Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Provexis's Gross Profit for the six months ended in Sep. 2023 was £0.14 Mil. Provexis's Revenue for the six months ended in Sep. 2023 was £0.39 Mil. Therefore, Provexis's Gross Margin % for the quarter that ended in Sep. 2023 was 35.57%.

Warning Sign:

Provexis PLC gross margin has been in long-term decline. The average rate of decline per year is -2.1%.


The historical rank and industry rank for Provexis's Gross Margin % or its related term are showing as below:

LSE:PXS' s Gross Margin % Range Over the Past 10 Years
Min: 46.75   Med: 89.66   Max: 95.61
Current: 46.75


During the past 13 years, the highest Gross Margin % of Provexis was 95.61%. The lowest was 46.75%. And the median was 89.66%.

LSE:PXS's Gross Margin % is ranked better than
50.66% of 989 companies
in the Drug Manufacturers industry
Industry Median: 46.51 vs LSE:PXS: 46.75

Provexis had a gross margin of 35.57% for the quarter that ended in Sep. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Provexis was -2.10% per year.


Provexis Gross Margin % Historical Data

The historical data trend for Provexis's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provexis Gross Margin % Chart

Provexis Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 84.78 89.66 90.30 89.20 75.38

Provexis Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.63 89.77 85.47 67.30 35.57

Competitive Comparison of Provexis's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Provexis's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provexis's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Provexis's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Provexis's Gross Margin % falls into.



Provexis Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Provexis's Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )=Gross Profit (A: Mar. 2023 ) / Revenue (A: Mar. 2023 )
=0.3 / 0.39
=(Revenue - Cost of Goods Sold) / Revenue
=(0.39 - 0.096) / 0.39
=75.38 %

Provexis's Gross Margin for the quarter that ended in Sep. 2023 is calculated as


Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=0.1 / 0.388
=(Revenue - Cost of Goods Sold) / Revenue
=(0.388 - 0.25) / 0.388
=35.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Provexis  (LSE:PXS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Provexis had a gross margin of 35.57% for the quarter that ended in Sep. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Provexis Gross Margin % Related Terms

Thank you for viewing the detailed overview of Provexis's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Provexis (LSE:PXS) Business Description

Traded in Other Exchanges
Address
2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ
Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is a patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.

Provexis (LSE:PXS) Headlines